Dyne Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company highlighted progress on its FORCE platform, with BLA filed for DMD Exon 51 and DM1 trial enrollment completed. Commercial launch is targeted for next year, with confirmatory studies underway and a robust pipeline in FSHD, Pompe, and additional DMD exons. Cash runway extends into 2028.
-
The discussion highlighted execution on DMD and DM1 programs, with commercial launches targeted for 2026 and a robust pipeline expansion leveraging the FORCE platform. Confirmatory trials are underway, regulatory engagement remains strong, and capital is being efficiently allocated to advance FSHD and other assets.
-
The company anticipates a pivotal year in 2026, with commercial launch preparations for DMD and a robust pipeline of eight clinical programs. Positive DMD data, regulatory alignment, and a differentiated platform support confidence in upcoming approvals and market entry.
-
FORCE platform clinically validated in DMD and DM1, enabling a robust pipeline of eight rare muscle disease programs. Zirasatersen shows strong efficacy and safety, with commercial launch planned for early 2026 and DM1 to follow. Market expansion includes four additional DMD exons, tripling addressable patients.
-
Two late-stage neuromuscular programs showed unprecedented efficacy and safety, with DYNE-251 for DMD and DYNE-101 for DM1 advancing toward regulatory submissions and commercial launches in 2027–2028. Platform validation, robust pipeline, and global regulatory alignment support long-term growth.
Fiscal Year 2025
-
The DELIVER trial for z-rostudirsen in DMD met its primary endpoint, showing a robust, statistically significant increase in dystrophin and improvement across all six functional endpoints, including ambulation, upper limb, and lung function. Safety was favorable, and sustained benefits were observed out to 24 months, supporting a planned BLA submission for accelerated approval in 2026.
-
The company is advancing late-stage programs in DMD and DM1, with product launches targeted for early 2027 and 2028. Robust clinical data show significant functional and biomarker improvements, supporting U.S. accelerated approval and a strong commercial opportunity.
-
Key milestones include a pivotal DMD data readout in December, BLA submission in 2026, and a planned launch in 2027. The DM1 program faces a short enrollment delay but remains on track for phase III. Both programs emphasize robust clinical endpoints and global expansion.
-
The company is advancing two neuromuscular therapies toward registration, with DMD and DM1 launches targeted for early 2027 and 2028, respectively. Robust clinical data, strong commercial preparation, and expansion plans for additional indications and exons position the pipeline for significant impact.
-
Recent industry acquisitions validate the neuromuscular therapeutic space and the company's approach. DMD program data is expected in December, showing strong dystrophin expression and functional gains, while DM1 enrollment delays are being addressed with expanded site capacity. Cost structure reflects accelerated development and trial scale.
-
The company is advancing two late-stage neuromuscular programs (DMD and DM1) with accelerated approval pathways, leveraging its FORCE platform for efficient genetic medicine delivery. Clinical data show strong efficacy and CNS benefits, with commercial launches targeted for 2027 and a robust pipeline expansion underway.
-
The company is advancing two lead neuromuscular programs, DMD and DM1, with top-line data expected by year end and a commercial launch targeted for early 2027. Its innovative platform enables efficient delivery and functional improvement, with a strong cash position supporting execution.
-
FDA Breakthrough Therapy Designation was granted for DYNE-101, with a revised accelerated approval plan using vHOT as the primary endpoint and expanded cohort size. New 12-month data show sustained efficacy and a favorable safety profile, supporting regulatory and commercial progress.
-
Late-stage DM1 and DMD programs are advancing, with regulatory filings planned next year and launches targeted for 2027. The DM1 program uses splicing correction as a surrogate endpoint for accelerated approval. DMD data show sustained benefit, and the platform has broad potential for neuromuscular and CNS indications.
-
The conference highlighted strong clinical progress in DM1 and DMD programs, with robust biomarker and functional data supporting accelerated approval pathways. The company is well-funded, advancing a broad pipeline, and expects to initiate a phase III DM1 trial and commercialize both lead programs by 2027.
-
Late-stage DM1 and DMD programs are advancing with robust clinical data, strong safety, and regulatory alignment for accelerated approval. The proprietary platform enables broad tissue delivery and supports expansion into FSHD and Pompe disease, with launches targeted for 2027.
-
New data from the ACHIEVE trial show Dyne-101 delivers robust DMPK knockdown, splicing correction, and broad functional improvements in DM1, including CNS benefits, with a favorable safety profile. The registrational cohort is set for completion in 2025, supporting a planned accelerated approval. Dyne-251 for DMD also advances with strong efficacy and safety, targeting a 2026 filing.
Fiscal Year 2024
-
The FORCE platform enables targeted delivery of oligonucleotides and biologics to muscle and CNS, with promising clinical results in DMD and DM1. Robust efficacy and safety data support ongoing registration cohorts, while pipeline expansion and strong financials position the company for rapid growth.
-
IND clearance for DM1 was achieved early, with key six- and twelve-month data to be released in January to guide dose selection and support an accelerated approval pathway. DMD program shows strong functional and dystrophin results, advancing rapidly with a large registrational cohort. FSHD and additional pipeline programs are progressing, highlighting the platform's versatility.
-
Neuromuscular programs in DM1 and DMD are advancing rapidly, with key data readouts and regulatory clarity supporting accelerated approval strategies. Safety remains strong across over 700 doses per program, and the platform is expanding into FSHD and Pompe with versatile payloads.
-
Strong funding and new leadership are driving rapid progress in two lead programs, DMD and DM1, both showing early functional benefits and advancing toward registration. The platform's versatility supports expansion into new indications, with regulatory engagement enabling accelerated paths.
-
Key leadership transitions were clarified, with new hires strengthening commercial and HR functions. DMD program data at 20 mg/kg showed significant functional improvements and strong safety, prompting initiation of registration cohorts. DM1 program demonstrated dose-dependent splicing and functional gains, with further data and regulatory updates expected by year-end.
-
The DELIVER phase 1/2 trial of DYNE-251 in DMD patients showed unprecedented dystrophin increases and meaningful functional improvements at 20 mg/kg, with a favorable safety profile and broad applicability across patient cohorts. Registrational cohorts are being initiated, and accelerated approval is being pursued globally.
-
Recent data for DMD and DM1 programs showed strong biomarker and functional improvements, prompting earlier-than-expected disclosure and positive FDA feedback on accelerated approval pathways. Dose escalation continues to yield consistent, durable benefits with a favorable safety profile.